8,974 Shares in PetIQ, Inc. (NASDAQ:PETQ) Bought by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in PetIQ, Inc. (NASDAQ:PETQ) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 8,974 shares of the company’s stock, valued at approximately $177,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Vanguard Group Inc. increased its position in PetIQ by 13.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,918,500 shares of the company’s stock valued at $37,794,000 after acquiring an additional 226,718 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of PetIQ by 13.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 416,878 shares of the company’s stock valued at $8,212,000 after purchasing an additional 50,647 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new position in shares of PetIQ in the fourth quarter valued at approximately $50,000. Acadian Asset Management LLC raised its stake in shares of PetIQ by 124.5% during the third quarter. Acadian Asset Management LLC now owns 38,600 shares of the company’s stock worth $759,000 after purchasing an additional 21,409 shares during the last quarter. Finally, Barclays PLC lifted its holdings in shares of PetIQ by 55.4% during the third quarter. Barclays PLC now owns 22,917 shares of the company’s stock worth $451,000 after purchasing an additional 8,173 shares during the period. 94.99% of the stock is owned by hedge funds and other institutional investors.

PetIQ Trading Down 0.4 %

Shares of PETQ opened at $17.58 on Wednesday. PetIQ, Inc. has a twelve month low of $11.31 and a twelve month high of $22.98. The company has a current ratio of 2.27, a quick ratio of 1.43 and a debt-to-equity ratio of 1.97. The firm has a market capitalization of $517.38 million, a P/E ratio of 293.05 and a beta of 1.68. The firm’s 50-day moving average is $17.06 and its two-hundred day moving average is $17.99.

PetIQ (NASDAQ:PETQ) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.22. The business had revenue of $219.93 million during the quarter, compared to analysts’ expectations of $189.70 million. PetIQ had a return on equity of 11.72% and a net margin of 0.19%. On average, research analysts predict that PetIQ, Inc. will post 0.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Jefferies Financial Group raised their price objective on shares of PetIQ from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, March 19th. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, PetIQ currently has a consensus rating of “Buy” and an average target price of $29.00.

PetIQ Company Profile

PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.